---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208918"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:45:36.134943+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer

## Summary
- Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.
- Q1 2026 net loss $453.8M vs $213.4M YoY; R&D $344M, G&A $101.3M, including $44.6M incremental SBC.
- Cash $1.9B at Mar 31, 2026; April 2026 financings raised $2.225B gross from stock and convertible notes.
- FY 2026 GAAP operating expense guidance raised to $1.7-1.8B due to ~$80M increase in non-cash SBC.
- Appointed Neil MacGregor JPAC GM, Tetsuo Endo Japan GM, Martin Voelkl Germany GM; EAP for daraxonrasib begun.

## SEC filing metadata
- accession: 0001193125-26-208918
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/0001193125-26-208918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/rvmd-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208918
- JSON: https://secwatch.observer/filing/0001193125-26-208918.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208918.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/0001193125-26-208918-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.